Aussara Panya

Chiang Mai, 50200, Thailand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

Corrigendum to "Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME)" [Biomed. Pharmacother. 200 (2026), 119609].

Corrigendum to "Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME)" [Biomed. Pharmacother. 200 (2026), 119609].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 01, 2026

Antibacterial Mechanisms and Skin-Protective Activities of Syzygium nervosum Leaf Extracts from Different Geographical Origins.

Antibacterial Mechanisms and Skin-Protective Activities of Syzygium nervosum Leaf Extracts from Different Geographical Origins.

Journal: International journal of molecular sciences

Published: June 02, 2026

Angiotensin I-Converting Enzyme Inhibitor Activity of Some Plants Used in Thai Indigenous Medicine.

Angiotensin I-Converting Enzyme Inhibitor Activity of Some Plants Used in Thai Indigenous Medicine.

Journal: Plants (Basel, Switzerland)

Published: May 19, 2026

Proof-of-concept engineering of Escherichia coli expressing a bee-derived cytochrome P450 monooxygenase for thiamethoxam detoxification.

Proof-of-concept engineering of Escherichia coli expressing a bee-derived cytochrome P450 monooxygenase for thiamethoxam detoxification.

Journal: Journal of biological engineering

Published: February 16, 2026

Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma.

Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma.

Journal: Cancer immunology, immunotherapy : CII

Published: December 31, 2025

Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME).

Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME).

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 29, 2025

Biomass-Haze PM2.5 from Northern Thailand Drives Genotype-Specific Oxidative Stress and Transcriptomic Remodeling in Non-Small-Cell Lung Cancer Cells.

Biomass-Haze PM2.5 from Northern Thailand Drives Genotype-Specific Oxidative Stress and Transcriptomic Remodeling in Non-Small-Cell Lung Cancer Cells.

Journal: Toxics

Published: November 27, 2025

Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors.

Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors.

Journal: Scientific reports

Published: November 02, 2025

Postbiotics combined with Caesalpinia sappan L. extract inhibit bovine mastitis bacterial pathogens, promote anti-inflammation and in vitro wound healing property.

Postbiotics combined with Caesalpinia sappan L. extract inhibit bovine mastitis bacterial pathogens, promote anti-inflammation and in vitro wound healing property.

Journal: Scientific reports

Published: September 29, 2025

Lactic Acid Bacteria Metabolites Modulate Immune Response Against Staphylococcus haemolyticus-Infected RAW264.7 Murine Macrophage: A Novel Approach for Bovine Mastitis.

Lactic Acid Bacteria Metabolites Modulate Immune Response Against Staphylococcus haemolyticus-Infected RAW264.7 Murine Macrophage: A Novel Approach for Bovine Mastitis.

Journal: Animals : an open access journal from MDPI

Published: September 21, 2025

Engineering a fifth-generation CAR T cells to overcome PD-L1-mediated immunosuppression in lung cancer.

Engineering a fifth-generation CAR T cells to overcome PD-L1-mediated immunosuppression in lung cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 02, 2025

Metabolic engineering of Escherichia coli for de novo production of lauryl glucoside.

Metabolic engineering of Escherichia coli for de novo production of lauryl glucoside.

Journal: Biodesign research

Published: July 09, 2025

Showing 1-12 of 81

Last Updated: 09/26/2026